When it comes to lario therapeutics awarded $2.4m by the michael j. fox foundation and wellcome to expand neuronal calcium channel platform across cns disorders, eDINBURGH, Scotland, Feb. 19, 2026 - Lario Therapeutics, a pioneering biopharmaceutical company specializing in precision medicines for neurological disorders, has been awarded $2.4 million in grant funding by The Michael J. Fox Foundation for Parkinson's Research (MJFF) and Wellcome. This funding aims to bolster the company's innovative neuronal calcium channel drug discovery platform, which seeks to address conditions like Parkinson's disease and post-traumatic stress disorder (PTSD).
Regarding lario therapeutics awarded .4m by the michael j. fox foundation and wellcome to expand neuronal calcium channel platform across cns disorders, The $1.5 million grant from MJFF is particularly aimed at advancing Lario's exploration of CaV1.3, a voltage-gated calcium channel that has been identified as a significant target in understanding the biology of Parkinson's disease. This target aligns with MJFF's Targets to Therapies initiative, which prioritizes drug targets that may alter the disease's progression. Meanwhile, Wellcome has provided $900,000 to validate CaV2.3 as a therapeutic target for PTSD, following recent large-scale genetic studies that have linked variations in the gene encoding CaV2.3 to an increased risk Of The disorder. Learn more about this topic on Wikipedia.
Understanding Lario Therapeutics Awarded $2.4m By The Michael J. Fox Foundation And Wellcome To Expand Neuronal Calcium Channel Platform Across CNS Disorders
Lario's recent grants underscore the company's commitment to tackling complex neurological diseases through cutting-edge science. The funding from MJFF will support Lario's ongoing research into the role of CaV1.3 in Parkinson's disease, a condition that affects millions worldwide and for which effective treatments remain limited.
Regarding lario therapeutics awarded .4m by the michael j. fox foundation and wellcome to expand neuronal calcium channel platform across cns disorders, Henning Steinhagen, CEO of Lario Therapeutics, expressed gratitude for the support from both MJFF and Wellcome, stating, "Lario was founded to translate strong human genetics and neuronal biology into precision medicines for patients with severe neurological disease." This sentiment resonates as the company continues its mission to develop first-in-class therapies tailored to the unique biological underpinnings of these conditions.
Groundbreaking Research on PTSD
Simultaneously, the grant from Wellcome marks a significant step towards understanding PTSD, a condition that affects a substantial portion of the population, particularly among military veterans and survivors of trauma. The connection between CaV2.3 and PTSD is particularly compelling, as it opens avenues for innovative treatments that target the underlying biological mechanisms of the disorder.
Regarding lario therapeutics awarded .4m by the michael j. fox foundation and wellcome to expand neuronal calcium channel platform across cns disorders, Recent studies have shown that variations in the gene CACNA1E, which encodes for CaV2.3, may increase the likelihood of developing PTSD. By investigating this connection, Lario hopes to contribute to the growing body of research that links neuronal calcium channel dysfunction to various neurological and psychiatric diseases.
Validation of Precision Neuroscience
The funding acquired from these reputable organizations serves as a validation of Lario's unique approach to precision neuroscience. The company's focus on selective small-molecule inhibitors of voltage-gated calcium channels positions it at the forefront of drug discovery in the field.
Regarding lario therapeutics awarded .4m by the michael j. fox foundation and wellcome to expand neuronal calcium channel platform across cns disorders, Tom Otis, Chief Scientific Officer at Lario Therapeutics, commented on the significance of the grants, stating, "These awards recognize the growing body of evidence linking neuronal calcium channel dysfunction to the core biology of neurological and psychiatric diseases." The integration of rigorous target biology with innovative chemistry is central to Lario's strategy, as it seeks to create a platform designed to develop effective treatments for conditions with high unmet medical needs.
Future Prospects and Clinical Applications
With the recent grants, Lario Therapeutics is positioned to make significant strides in both Parkinson's disease and PTSD research. The company is building on its previously announced $6 million grant from MJFF awarded in 2024, which supports preclinical work on CaV2.3 as a potential therapeutic target for Parkinson's.
Regarding lario therapeutics awarded .4m by the michael j. fox foundation and wellcome to expand neuronal calcium channel platform across cns disorders, The convergence of funding from MJFF and Wellcome not only illustrates the confidence these organizations have in Lario's research capabilities but also highlights the urgency of developing new treatment options for debilitating neurological and psychiatric disorders. As Lario advances its drug discovery initiatives, the hope is to translate these scientific insights into real-world treatments that can improve the quality of life for patients suffering from these conditions.
Regarding lario therapeutics awarded .4m by the michael j. fox foundation and wellcome to expand neuronal calcium channel platform across cns disorders, In summary, Lario Therapeutics' successful acquisition of the $2.4 million grant funding marks a critical juncture in the company's journey to address unmet medical needs in neurological health. As it further develops its neuronal calcium channel platform, Lario is one step closer to offering meaningful therapeutic options for patients facing the challenges of Parkinson's disease and PTSD.